The cost-effectiveness of interleukin-1 genetic testing for periodontal disease

Journal of Periodontology

Volumn 73, Issue 12, 2002, Pages 1474-1484

  Higashi, Mitchell K ^a,b   Veenstra, David L ^a,b   del Aguila, Michael ^c,d   Hujoel, Philippe ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Institute for Public Health Genetics   (United States)

^c Division of Public Health Sciences   (United States)

^d Washington Dental Service   (United States)

Author keywords

Cost benefit analysis; Disease progression; Genotypes; Interleukin 1; Models, biological; Periodontal diseases; Risk factors

Indexed keywords

INTERLEUKIN 1;

ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION MAKING; DISEASE COURSE; DISEASE SEVERITY; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; MAINTENANCE THERAPY; PATIENT COMPLIANCE; PERIODONTAL DISEASE; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; SIMULATION; TREATMENT OUTCOME;

ADULT; COST-BENEFIT ANALYSIS; DECISION TREES; DENTAL PROPHYLAXIS; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; INTERLEUKIN-1; MALE; MARKOV CHAINS; MODELS, BIOLOGICAL; PATIENT COMPLIANCE; PERIODONTITIS; PREDICTIVE VALUE OF TESTS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SMOKING CESSATION;

EID: 0036962281     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2002.73.12.1474     Document Type: Article

References (46)

1. Albandar JM, Brunelle JA, Kingman A. Destructive periodontal disease in adults 30 years of age and older in the United States, 1988-1994. J Periodontol 1999;70:13-29.
2. Hirschfeld L, Wasserman B. A long-term survey of tooth loss in 600 treated periodontal patients. J Periodontol 1978;49:225-237.
3. Haber J, Kent RL. Cigarette smoking in a periodontal practice. J Periodontol 1992;63:100-106.
4. McGuire MK, Nunn ME. Prognosis versus actual outcome. II. The effectiveness of clinical parameters in developing an accurate prognosis. J Periodontol 1996; 67:658-665.
5. McGuire MK, Nunn ME. Prognosis versus actual outcome. IV. The effectiveness of clinical parameters and IL-1 genotype in accurately predicting prognoses and tooth survival. J Periodontol 1999;70:49-56.
6. Kalkwarf KL, Kaldahl WB, Patil KD. Evaluation of furcation region response to periodontal therapy. J Periodontol 1988;59:794-804.
7. Hujoel PP, Leroux BG, Selipsky H, White BA. Non-surgical periodontal therapy and tooth loss. A cohort study. J Periodontol 2000;71:736-742.
8. Birkedal-Hansen H. Role of cytokines and inflammatory mediators in tissue destruction. J Periodont Res 1993; 28: 500-510.
9. Kornman KS, Giovine FS. Genetic variations in cytokine expression: A risk factor for severity of adult periodontitis. Ann Periodontol 1998;3:327-338.
10. Kornman KS, Crane A, Wang H-Y, et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997;24:72-77.
11. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:322-338.
12. Chace R, Low SB. Survival characteristics of periodontally-involved teeth: A 40-year study. J Periodontol 1993;64:701-705.
13. U.S. Bureau of the Census (1996). Statistical Abstract of the United States 1996. Section 2, Vital Statistics. Available at: http://www.census.gov/prod/www/statistical-abstract-us.html. Accessed January 20, 2002.
14. Mendez D, Warner KE, Courant PN. Has smoking cessation ceased? Expected trends in the prevalence of smoking in the United States. Am J Epidemiol 1998; 148:249-258.
15. Krall EA, Garvey AJ, Garcia RI. Alveolar bone loss and tooth loss in male cigar and pipe smokers. J Am Dent Assoc 1999;130:57-64.
16. Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from higher dose nicotine patch therapy? Exp Clin Psychopharmacol 1999;7:226-233.
17. Stapleton JA, Russell MA, Feyerabend C, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 1995;90:31-42.
18. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: A placebo-controlled clinical trial. Prev Med 1995;24:41-47.
19. Daughton D, Susman J, Sitorius M, et al. Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group. Arch Fam Med 1998; 7:425-430.
20. Sachs DP, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 1993;153:1881-1890.
21. Checchi L, Pelliccioni G, Gatto M. Patient compliance with maintenance therapy in an Italian periodontal practice. J Clin Periodontol 1994;21:309-312.
22. Demetriou N, Tsami-Pandi A, Parashis A. Compliance with supportive periodontal treatment in private periodontal practice. A 14-year retrospective study. J Periodontol 1995;66:145-149.
23. Mendoza AR, Newcomb GM, Nixon KC. Compliance with supportive periodontal therapy. J Periodontol 1991;62: 731-736.
24. Wilson TG, Glover ME, Schoen J, Baus C, Jacobs T. Compliance with maintenance therapy in a private periodontal practice. J Periodontol 1984;55:468-473.
25. Wilson TG Jr., Hale S, Temple R. The results of efforts to improve compliance with supportive periodontal treatment in a private practice. J Periodontol 1993;64:311-314.
26. Tan AE, Powell RN, Seymour GJ. Patient attendance compliance in periodontal therapy. Aust Dent J 1992; 37:467-471.
27. Locker D, Clarke M, Payne B. Self-perceived oral health status, psychological well-being, and life satisfaction in an older adult population. J Dent Res 2000;79:970-975.
28. Slade GD. Assessing change in quality of life using the Oral Health Impact Profile. Community Dent Oral Epidemiol 1998;26:52-61.
29. Slade GD, Spencer AJ, Locker D, Hunt RJ, Strauss RP, Beck JD. Variations in the social impact of oral conditions among older adults in South Australia, Ontario, and North Carolina. J Dent Res 1996;75:1439-1450.
30. Guckes AD, Scurria MS, Shugars DA. A conceptual framework for understanding outcomes of oral implant therapy. J Prosthet Dent. 1996;75:633-639.
31. Center for Disease Control resources page. Center for Disease Control Web site. Third National Health and Nutrition Examination Survey (NHANES III). Available at:http://www.cdc.gov/. Accessed January 10, 2002.
32. Gold MR, Siegal JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. Oxford, England: Oxford University Press; 1997:214-221.
33. Leske MC, Ederer F, Podgor M. Estimating incidence from age-specific prevalence in glaucoma. Am J Epidemiol 1981;113:606-613.
34. Briggs A, Sculpher M. An introduction to Markov modeling for economic evaluation. Pharmacoeconomics 1998;13:397-409.
35. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford, England: Oxford University Press; 1997:139-199.
36. Patrick DL, Erickson P. Health Status and Health Policy. Allocating Resources to Health Care. Oxford, England: Oxford University Press; 1993:143-180.
37. Wei N, Nakama H, Li T. Screen compliance rates in 14-years annual screening program for colorectal cancer with immunochemical fecal occult blood test-identification of higher priority subjects in health education. Eur J Med Res 1998;3:341-344.
38. Armitage GC, Wu Y, Wang HY, Sorrell J, di Giovine FS, Duff GW. Low prevalence of the periodontitis-associated interleukin-1 composite genotype in individuals of Chinese heritage. J Periodontol 2000;71:164-171.
39. Walker SJ, Van Dyke TE, Rich S, Kornman KS, di Giovine FS, Hart TC. Genetic polymorphisms of the IL-1 alpha IL- 1 beta genes in African-American LJP patients and an African-American control population. J Periodontol 2000;71:723-728.
40. Cox A, Camp NJ, Cannings C, et al. Combined sib-TDT and TDT provide evidence for linkage of the interleukin-1 gene cluster to erosive rheumatoid arthritis. Hum Mol Genet 1999;8:1707-1713.
41. Jouvenne P, Chaudhary A, Buchs N, Giovine FS, Duff GW, Miossec P. Possible genetic association between interleukin-1 alpha gene polymorphism and the severity of chronic polyarthritis. Eur Cytokine Netw 1999; 10:33-36.
42. Francis SE, Camp NJ, Dewberry RM, et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999;99:861-866.
43. Nemetz A, Nosti-Escanilla MP, Molnar T, et al. IL1B gene polmorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 1994; 49: 527-531.
44. O'Brien-Simpson NM, Paolini RA, Reynolds EC. RgpA-Kgp peptide-based immunogens provide protection against Poryphyromonas gingivalis challenge in a murine lesion model. Infect Immun 2000;68:4055-4063.
45. Katoh M, Saito S, Takiguchi H, Abiko Y. Bactericidal activity of a monoclonal antibody against a recombinant 40-kDa outer membrane protein of Porphyromonas gingivalis. J Periodontol 2000;71:368-375.
46. Kozarov E, Miyashita N, Burks J, et al. Expression and immunogenicity of hemagglutinin A from Porphyromonas gingivalis in an avirulent Salmonella enterica serovar typhimurium vaccine strain. Infect Immun 2000; 68:732-739.